评估结直肠癌新型非侵入性筛查试验的高效策略:指导原则
本文通过多学科专家小组的正式共识方法修订了既往八项原则,提出十二项新原则。新试验可与已验证的非侵入性比较试验对比评估,粪便免疫化学试验现被视为合适的比较对象,结肠镜仍为诊断标准。文章提出四阶段评估方法,从小型研究到重复筛查轮次评估,以生成无偏人群数据预测健康影响。
要点
- 新试验可与已验证的非侵入性比较试验对比评估,粪便免疫化学试验为合适比较对象。
- 建议采用四阶段评估方法:I期辨别结直肠癌与非癌状态,II期在富肿瘤人群中前瞻性评估准确性。
- III期确定单轮筛查项目结局并确认阳性阈值,IV期评估重复筛查轮次并监测漏诊病变。
核心结论
- 新型非侵入性试验可通过严格的阶段性比较方法高效评估,生成无偏人群数据以预测其健康影响。
研究设计与样本
- 采用正式共识方法,由多学科专家小组修订既往八项原则。
主要发现
- 共提出十二项新原则。
- 新试验的有效性可通过与已验证的非侵入性比较试验对比评估。
- 粪便免疫化学试验现被视为合适的比较对象,结肠镜仍为诊断标准。
- 新试验宜具备调整阳性阈值的灵活性,以满足不同筛查目标和监管要求。
- 提出四阶段评估方法:I期小型研究评估辨别结直肠癌与非癌状态的能力;II期在富肿瘤人群中前瞻性评估跨肿瘤性病变连续谱的准确性;III期前瞻性研究确定单轮意向筛查项目结局并确认阳性阈值;IV期评估重复筛查轮次并监测漏诊病变。
关键数值与推荐
- 粪便免疫化学试验为合适的比较对象。
- 结肠镜仍为诊断标准。
- 新试验宜具备调整阳性阈值的灵活性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: New screening tests for colorectal cancer (CRC) are rapidly emerging. Conducting trials with mortality reduction as the end point supporting their adoption is challenging. We re-examined the principles underlying evaluation of new non-invasive tests in view of technological developments and identification of new biomarkers. DESIGN: A formal consensus approach involving a multidisciplinary expert panel revised eight previously established principles. RESULTS: Twelve newly stated principles emerged. Effectiveness of a new test can be evaluated by comparison with a proven comparator non-invasive test. The faecal immunochemical test is now considered the appropriate comparator, while colonoscopy remains the diagnostic standard. For a new test to be able to meet differing screening goals and regulatory requirements, flexibility to adjust its positivity threshold is desirable. A rigorous and efficient four-phased approach is proposed, commencing with small studies assessing the test's ability to discriminate between CRC and non-cancer states (phase I), followed by prospective estimation of accuracy across the continuum of neoplastic lesions in neoplasia-enriched populations (phase II). If these show promise, a provisional test positivity threshold is set before evaluation in typical screening populations. Phase III prospective studies determine single round intention-to-screen programme outcomes and confirm the test positivity threshold. Phase IV studies involve evaluation over repeated screening rounds with monitoring for missed lesions. Phases III and IV findings will provide the real-world data required to model test impact on CRC mortality and incidence. CONCLUSION: New non-invasive tests can be efficiently evaluated by a rigorous phased comparative approach, generating data from unbiased populations that inform predictions of their health impact.
引用
- Bresalier RS, Senore C, Young GP, et al. An efficient strategy for evaluating new non-invasive screening tests for colorectal cancer: the guiding principles. Gut. 2023. PMID: 37463757. doi:10.1136/gutjnl-2023-329701
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。